Researchers analyzed data from several studies involving patients with advanced or metastatic renal cell carcinoma with sarcomatoid differentiation. They compared the effectiveness of PD-1 and PD-L1 inhibitor-based regimens against a standard treatment called sunitinib. The study looked at how well tumors shrank and how long patients lived without the disease progressing.
The results showed that patients receiving PD-1 or PD-L1 inhibitors had a significantly higher objective response rate and a higher rate of complete response compared to those taking sunitinib. Additionally, the data indicated a lower risk of disease progression for those on the newer inhibitor-based regimens.
While the findings for response rates and progression-free survival were consistent, the evidence for overall survival was less certain because it was not statistically significant in all parts of the analysis. Because the evidence for overall survival is less robust, these results should be viewed as promising but not definitive. Patients should discuss these specific treatment options with their oncology team to determine the best plan for their individual case.
